BioCrine
  • Home
  • About Us
    • Company and People
    • Board of Directors
    • Management
    • Partners
  • Research Programs
    • Pipeline overview
    • Diabetes as a disease
    • Biocrine drug discovery strategy
    • Serum factor apoCIII
    • Insulin receptor isoforms
    • Calcium channels
    • Inositol pyrophosphates
  • InSight Technology
    • What is it?
    • How does it work?
    • Where can it be used?
  • News
  • Contact
Home » Research Programs » Biocrine drug discovery strategy

Biocrine drug discovery strategy

Biocrine is dedicated to find a solution for diabetes, a disease that affects millions of people around the globe. The research we aim to commercialize is funneled into four key areas around different aspects of diabetes progression and molecular reactions:

  1. Enhancement of insulin release only at high blood sugar levels
    • Make insulin release by beta-cells more sensitive to glucose: Only high blood sugar levels should result in insulin release. At normal or low levels, insulin should not be released by the beta-cells. Unnecessary high insulin release may result in insulin resistance and cancer.
  2. Suppression of glucagon release
    • At high blood sugar levels, glucagon release by alpha-cells should be suppressed: The more glucagon, the more glucose is released by liver, leading to even higher blood sugar levels. Too much glucagon represents one of the defects of type 2-diabetes. Adequate glucagon release is important for regulation of blood glucose concentration.
  3. Preservation of beta cell mass
    • Preserve beta cell mass in the endocrine pancreas.

The Research programs at Biocrine are well-defined and novel. Each program addresses at least one of the key areas.

 

Research Programs

  • Pipeline overview
  • Diabetes as a disease
  • Biocrine drug discovery strategy
  • Serum factor apoCIII
  • Insulin receptor isoforms
  • Calcium channels
  • Inositol pyrophosphates

Biocrine AB

Box 3073

169 03 Solna, Sweden

Contact Us

info at biocrine.se

www.biocrine.com

Copyright © 2012 Biocrine AB. All Rights Reserved